A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT03684265
- Locations
- 🇷🇺
City Clinical Hospital named after V.P. Demikhova Department of Health of Moscow, Moscow, Russian Federation
A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 17
- Registration Number
- NCT03675581
- Locations
- 🇪🇸
Hospital Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Vall d'Hebron, Barcelona, Spain
🇳🇱Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
A Study in Healthy Men to Test How BI 730357 is Processed by the Body
- Conditions
- Healthy
- Interventions
- Drug: BI 730357 mixed with [C-14]BI 730357 BS
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6
- Registration Number
- NCT03664011
- Locations
- 🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands
A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4819
- Registration Number
- NCT03663569
- Locations
- 🇧🇬
MBAL Kiro Popov EOOD, Karlovo, Bulgaria
🇧🇬MBAL Sv. Ivan Rilski EOOD, Kozloduj, Bulgaria
🇧🇬MBAL Sliven to VMA Sofia, Sliven, Bulgaria
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 103
- Registration Number
- NCT03659136
- Locations
- 🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇺🇸Cancer Treatment Centers of America at Western Regional Medical Center, Goodyear, Arizona, United States
A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body
- Conditions
- Healthy
- Interventions
- Drug: BI 425809 mixed with [C-14] BI425809
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6
- Registration Number
- NCT03654170
- Locations
- 🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 79
- Registration Number
- NCT03648541
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Southern Star Research Institute, LLC, San Antonio, Texas, United States
Regulatory Request NIS in Korea
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 658
- Registration Number
- NCT03642717
- Locations
- 🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of
🇰🇷Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷Korea University Ansan Hospital, Ansan, Korea, Republic of
This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is
- Conditions
- Psoriasis
- Interventions
- Drug: BI 50 mg (fasted)Drug: BI 100 mg (fasted)Drug: BI 200 mg (fasted)Drug: Placebo (fed)Drug: BI 400 mg once daily (fed)Drug: BI 200 mg twice daily, 400 mg total (fed)Drug: Placebo (fasted)Drug: BI 25 mg (fasted)
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 274
- Registration Number
- NCT03635099
- Locations
- 🇺🇸
Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT03629054
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany